EVALUATION OF IMMUNE-BASED THERAPIES FOR AIDS USING ANIMAL MODELS 

RFP AVAILABLE:  NIAID-DAIDS-92-15 (see erratum not92-019)

 

P.T. 34



Keywords:

  AIDS 

  Immunotherapy 

  Disease Model 

 

National Institute of Allergy and Infectious Diseases

 

The Developmental Therapeutics Branch, Basic Research and Development

Program, Division of AIDS, National Institute of Allergy and Infectious

Diseases (NIAID), has a requirement for the evaluation of immune-based

therapies for AIDS using animal models.  This procurement consists of

two parts that seek testing capabilities for immune-based therapies

that target different types of immune deficiencies seen in HIV

infection and AIDS.  The two parts are entitled, "Part A - Evaluation

of Immune-Based Therapies to Augment or Normalize Immune Function" and

"Part B - Evaluation of Multipotent Stem Cell Reconstitution as a

Therapy to Restore Immune Cell Deficits".

 

"Part A" of this procurement will provide for the evaluation of

immune-based therapies in an established small-animal model, alone or

in combination with other therapies, for their capacity to augment

host-defense mechanisms or otherwise ameliorate immune dysfunctions

characteristic of HIV infection. Emphasis will be placed on aspects of

immune-based therapies, i.e., mechanism of action, optimal scheduling,

identification of quantifiable parameters related to in vivo efficacy,

potential for positive or negative interaction between immune-based and

anti-retroviral therapies, and the potential of immune-based therapies

to upregulate virus expression.  An established and validated animal

model is required for Part A.  "Part B" of this procurement will

provide for development, validation, and testing of a model in which an

immunodeficient animal is reconstituted with a source of human

multipotent stem cells that can re-establish the immune system and that

may also be genetically modified to resist subsequent infection with

HIV-1.

 

The offeror shall, at the time of proposal, have identified an animal

system to be developed and validated and a source of human multipotent

stem cells.  These capabilities are required by the Division of AIDS,

NIAID, in its efforts to develop immune-based therapies for human

subjects infected with HIV-1.  There will be separate work statements

and competitive ranges established for each part.  Offerors may respond

to one or more parts.  It is anticipated that one or more awards will

be made for Part A and one award will be made for Part B.  If more than

one award is made for Part A, the Government reserves the right to make

only one award per animal model.  This NIAID-sponsored project will

take approximately five years to complete.  A cost-reimbursement

contract is anticipated.

 

This is an announcement for an anticipated Request for Proposal (RFP).

RFP NIAID-DAIDS-92-15 shall be issued on or about January 20, 1992,

with a closing date tentatively set for March 20, 1992.  Requests for

the RFP shall be directed in writing to:

 

Cyndie Cotter

Contract Management Branch

National Institute of Allergy and Infectious Diseases

Solar Building, Room 3C-07

6003 Executive Boulevard

Bethesda, MD  20892

 

To receive a copy of the RFP, supply this office with two

self-addressed labels.  All responsible sources may submit a proposal

that will be considered.

 

This announcement does not commit the Government to award a contract.

 

.

Return to 1992 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)